This comparison is based on separate clinical trials with different populations, durations, and protocols—not a direct head-to-head study. All comparative statements are indirect comparisons and should be interpreted with caution. A direct comparison trial is needed for definitive conclusions.
At a Glance
Direct Comparison
No direct head-to-head trial comparing retatrutide and tirzepatide has been conducted. All efficacy and safety comparisons are based on separate clinical trials with different study designs, patient populations, treatment durations, and endpoints.
When comparing drugs from separate trials, we cannot definitively conclude which is "better" because:
- Different populations: Baseline characteristics, demographics, and inclusion/exclusion criteria differ
- Different trial phases: Retatrutide Phase 2 (smaller, earlier-stage) vs Tirzepatide Phase 3 (larger, registration trials)
- Different durations: Retatrutide 48 weeks vs Tirzepatide 72 weeks
- Different protocols: Dose escalation schedules, concomitant medications, and monitoring procedures vary
Network Meta-Analysis: Retatrutide vs Tirzepatide
A 2025 network meta-analysis published in the Journal of the Endocrine Society attempted to compare retatrutide and tirzepatide using indirect comparison methodology:[3]
| Metric | Retatrutide | Orforglipron | Interpretation |
|---|---|---|---|
| Percentage Weight Loss | −23.77% | −16.79% | Retatrutide greater (indirect) |
| Adverse Event Risk Ratio | 4.10 | 2.78 | Retatrutide higher AE rate |
| Comparison Type | INDIRECT Network meta-analysis methodology | Not head-to-head data | |
Interpretation: This meta-analysis suggests retatrutide may have greater weight loss efficacy, but with a higher adverse event rate. However, these conclusions are based on indirect comparisons and should be viewed as preliminary until a direct head-to-head trial is conducted.
Effectiveness
Below we compare efficacy outcomes from the primary trials for each drug. Remember: These were separate trials—comparisons are indirect and should be interpreted with caution.
Weight Loss Efficacy
| Drug & Dose | Mean Weight Loss (%) | ≥10% Loss | ≥20% Loss | Trial & Duration | Comparison Type |
|---|---|---|---|---|---|
| Retatrutide 12mg | −24.2% | ~75% (est.) | ~50% (est.) | Phase 2: 48 weeks (n=338) | INDIRECT |
| Tirzepatide 15mg | −22.5% | 83% | 63% | SURMOUNT-1: 72 weeks (n=2,539) | INDIRECT |
| Tirzepatide 10mg | −21.4% | 79% | 55% | SURMOUNT-1: 72 weeks (n=2,539) | INDIRECT |
Interpretation: Both drugs demonstrate remarkable weight loss efficacy exceeding 20% mean reduction. Retatrutide's 24.2% weight loss at 48 weeks (Phase 2) is impressive, but was achieved in a smaller, earlier-stage trial. Tirzepatide's 22.5% weight loss at 72 weeks was demonstrated in a large Phase 3 registration trial. The longer duration of the tirzepatide trial may explain why responder rates (≥20% loss) appear higher for tirzepatide. Retatrutide's Phase 3 TRIUMPH trials will provide more comparable data.[1,2]
Type 2 Diabetes: A1C Reduction
| Drug & Dose | Mean A1C Reduction | Trial & Population | Comparison Type |
|---|---|---|---|
| Retatrutide 12mg | −2.02% | Phase 2: T2D + obesity | INDIRECT |
| Tirzepatide 15mg | −2.1% | SURPASS-2: T2D | INDIRECT |
Interpretation: Both drugs demonstrate strong A1C reduction in people with type 2 diabetes, with similar efficacy (~2% reduction). Tirzepatide has extensive Phase 3 data from the SURPASS program demonstrating consistent A1C lowering across multiple trials. Retatrutide's diabetes efficacy will be further evaluated in the ongoing TRIUMPH-4 trial.[1]
Tolerability
As GIP + GLP-1 receptor agonists, both drugs share similar gastrointestinal side effect profiles. Retatrutide's additional glucagon receptor activation may contribute to slightly higher GI event rates observed in Phase 2 trials.
Gastrointestinal Side Effects
| Side Effect | Retatrutide (Phase 2) | Tirzepatide (SURMOUNT-1) | Note |
|---|---|---|---|
| Nausea | 60-80% (high doses) | 18-29% (dose-dependent) | Retatrutide higher in Phase 2 |
| Diarrhea | Common | 21% | Similar |
| Vomiting | Common | 11% | Similar |
| Discontinuation Rate | 6-16% | 4.3-7.1% | Slightly higher with retatrutide |
| Severity | Mostly mild-moderate | Mostly mild-moderate | Similar |
Interpretation: Gastrointestinal side effects are common with both drugs, occurring primarily during dose escalation. Retatrutide's nausea rates (60-80%) appear higher than tirzepatide (18-29%), but important context: Retatrutide data is from Phase 2 trials with aggressive dose escalation protocols. Phase 3 TRIUMPH trials employ refined dosing schedules (starting at 2mg instead of 4mg) which may improve tolerability. Most GI events are mild-moderate, transient, and improve with continued treatment for both drugs.[1,2]
Retatrutide's safety profile is based on Phase 2 trials, which typically:
- Have smaller sample sizes (n=338 vs n=2,539)
- Use more aggressive dose escalation to test tolerability limits
- May not reflect optimized dosing schedules
Phase 3 TRIUMPH trials will provide more comprehensive safety data with refined dosing protocols.
Both drugs carry class warnings for GLP-1 receptor agonists:
- Contraindicated: Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Warnings: Risk of thyroid C-cell tumors (based on rodent studies), pancreatitis, diabetic retinopathy complications, hypoglycemia (when combined with insulin or sulfonylureas)
Real-World Use
Both drugs offer similar convenience as once-weekly injections without food restrictions. Key differences lie in availability and device design.
Dosing & Administration Comparison
| Factor | Retatrutide | Orforglipron |
|---|---|---|
| Route | Subcutaneous injection | Subcutaneous injection |
| Frequency | Once weekly | Once weekly |
| Food requirements | ✓ None | ✓ None |
| Timing flexibility | Any time, any day | Any time, any day |
| Needles required | Yes (weekly) | Yes (weekly) |
| Device | TBD (Phase 3) | Pre-filled single-dose pen |
| Dose Escalation | 2mg → 4mg → 8mg → 12mg (every 4 weeks) | 2.5mg → 5mg → 10mg → 15mg (every 4 weeks) |
Key Similarities: Both drugs offer similar convenience with once-weekly subcutaneous injections, no food restrictions, and flexible timing. Both require gradual dose escalation to minimize gastrointestinal side effects.
Key Difference: Tirzepatide is available now with a well-designed pre-filled pen device. Retatrutide's delivery device will be finalized during Phase 3 development.
Access
Availability represents the most critical difference between these drugs. Tirzepatide is FDA-approved and commercially available now; retatrutide is 2-3 years away from potential approval.
Availability Status (2025)
✓ Tirzepatide (Available Now)
- FDA-approved May 2022 (Mounjaro for type 2 diabetes)
- FDA-approved November 2023 (Zepbound for obesity)
- Commercially available with prescription
- Widely distributed, minimal supply issues
- Extensive real-world data (millions of prescriptions)
⏳ Retatrutide (Investigational)
- Phase 3 TRIUMPH trials ongoing (2024-2025)
- Access: Clinical trial enrollment only
- FDA submission expected late 2025-2026
- Approval timeline: 2026-2027 (if successful)
- Commercial availability: 2027 (projected)
Cost Comparison
| Drug | List Price (Monthly) | Current Cost | Availability |
|---|---|---|---|
| Retatrutide | Not yet announced | Free (clinical trials) Medication + monitoring provided | Investigational |
| Tirzepatide (Mounjaro/Zepbound) | $1,000-$1,350 | $0-$550 copay with insurance Up to $550 off with savings card | Approved |
Insurance Coverage Landscape
Type 2 Diabetes (Mounjaro):
- Widely covered by most commercial and Medicare Part D plans
- Typical tier: Tier 3-4 (Specialty)
- Prior authorization usually required
- Step therapy may apply (metformin first)
Obesity (Zepbound):
- Variable coverage—many plans exclude obesity medications
- If covered: Tier 3-4, prior authorization required
- Some employers/states expanding coverage
Patient Assistance:
- Manufacturer savings card: Up to $550 off/month (commercial insurance only)
- Lilly Cares Foundation: Zepbound, Mounjaro and Foundayo are not on Lilly Cares’ medication list
Coverage policies will be determined after FDA approval. Expected patterns based on similar drugs:
- Likely Tier 3-4 placement (specialty medication)
- Prior authorization expected
- Step therapy requirements likely
- Obesity indication may face coverage barriers (many plans exclude)
- Manufacturer patient assistance programs typically offered
Need help with insurance coverage? Honest Care specializes in helping patients navigate insurance barriers and appeal denials for GLP-1 medications. Start your appeal assessment →
Which to Choose
Choosing between retatrutide and tirzepatide depends on individual patient factors, timing needs, and availability. Currently, only tirzepatide is available—retatrutide remains 2-3 years away from potential approval.
Consider Tirzepatide (Mounjaro/Zepbound) If:
- You need treatment NOW (not 2-3 years from now)
- You want FDA-approved medication with proven track record
- You have type 2 diabetes (Mounjaro is indicated)
- Your insurance covers it (many plans cover diabetes indication)
- You value extensive real-world safety data (millions of prescriptions)
- You want manufacturer savings card option (up to $550 off/month)
- You prefer dual-agonist mechanism (GIP + GLP-1)
Consider Retatrutide (Clinical Trials) If:
- You're willing to wait 2-3 years for FDA approval
- You want to participate in clinical trials (free medication + monitoring)
- You're interested in triple-agonist mechanism (potential for higher efficacy)
- You didn't tolerate tirzepatide well (may have different profile)
- You want to contribute to scientific research
- You meet TRIUMPH trial inclusion criteria (obesity or T2D + obesity)
- You live near a trial site and can commit to frequent visits
Timeline
Retatrutide is currently in Phase 3 development. Based on Eli Lilly's public statements and typical FDA review timelines, here's the projected path to approval:
If you need treatment now: Tirzepatide is your only option. It's FDA-approved, commercially available, and highly effective.
If you can wait: Consider enrolling in TRIUMPH clinical trials to access retatrutide for free while contributing to research. Visit ClinicalTrials.gov and search "retatrutide TRIUMPH" to find active trials near you.
Bottom line: Tirzepatide is proven and available now. Retatrutide is promising but 2-3 years away.
FAQs
Based on separate trials (indirect comparison):
Retatrutide: 24.2% mean weight loss at 48 weeks (Phase 2, n=338, 12mg dose).[1]
Tirzepatide: 22.5% mean weight loss at 72 weeks (SURMOUNT-1, n=2,539, 15mg dose).[2]
Important context: These results are from separate trials with different durations, populations, and study phases. Retatrutide's triple-agonist mechanism (adding glucagon receptor) may confer additional weight loss benefits, but a head-to-head trial is needed for definitive conclusions. Both drugs demonstrate remarkable efficacy exceeding 20% mean weight loss.
Both drugs have similar gastrointestinal side effect profiles (nausea, diarrhea, vomiting), as they both activate GIP + GLP-1 receptors.
Retatrutide (Phase 2): Nausea rates of 60-80% at higher doses, 6-16% discontinuation rate.[1]
Tirzepatide (SURMOUNT-1): Nausea rates of 18-29% (dose-dependent), 4.3-7.1% discontinuation rate.[2]
Important context: Retatrutide's higher GI side effect rates are from Phase 2 trials with aggressive dose escalation. Phase 3 TRIUMPH trials employ refined dosing schedules (starting at 2mg instead of 4mg) which may improve tolerability. Most GI side effects are mild-moderate and improve over time with both drugs. Individual tolerance varies significantly.
No. Retatrutide is investigational and not FDA-approved. You can only access it through clinical trial enrollment.
How to access retatrutide:
- Visit ClinicalTrials.gov and search "retatrutide TRIUMPH"
- Review inclusion/exclusion criteria for active trials
- Contact trial sites near you for screening
- Trial participation is free (medication + monitoring provided)
If you need treatment now: Tirzepatide (Mounjaro/Zepbound) is FDA-approved and commercially available.
Potentially, but not definitively proven.
Triple-agonist mechanism (retatrutide):
- GIP + GLP-1: Increase insulin, decrease appetite, slow gastric emptying (shared with tirzepatide)
- Glucagon (unique): Increases energy expenditure and fat burning[6]
The addition of glucagon receptor activation may explain retatrutide's slightly higher weight loss in Phase 2 trials (24.2% vs 22.5%). However, it also may contribute to higher GI side effects. Phase 3 TRIUMPH trials will clarify the risk-benefit profile.
Bottom line: More mechanisms doesn't automatically mean "better"—it depends on the balance of efficacy and tolerability for each individual patient.
Projected timeline:
- 2024-2025: Phase 3 TRIUMPH trials ongoing
- Late 2025-2026: FDA submission expected (if trials successful)
- 2026-2027: FDA approval decision (typical review: 10-12 months)
- 2027: Commercial availability (if approved)
This means retatrutide is approximately 2-3 years away from potential approval. Tirzepatide is available now.
Tirzepatide (Current):
- Diabetes (Mounjaro): Widely covered (Tier 3-4), prior authorization often required
- Obesity (Zepbound): Variable coverage—many plans exclude obesity medications
- Savings card: Up to $550 off/month (commercial insurance only)
Retatrutide (Future—If Approved):
- Coverage policies will be determined after FDA approval
- Expected to face similar barriers as other weight loss medications
- Likely Tier 3-4 placement with prior authorization
Need help with insurance appeals? Start your assessment with Honest Care →
No. Both drugs are GLP-1 receptor agonists and should not be combined. Using multiple GLP-1 agonists together:
- Increases side effect risk (especially GI side effects)
- Does not provide additional benefit
- Is not supported by clinical evidence
- Could lead to hypoglycemia (low blood sugar) if you have diabetes
If you're considering switching from tirzepatide to retatrutide (or vice versa), discuss a safe transition plan with your healthcare provider.
No. No head-to-head trial comparing retatrutide and tirzepatide has been conducted. All comparisons in this article are indirect, based on separate clinical trials with different study designs, populations, and durations.
What we have:
- Network meta-analyses (indirect comparison methodology)
- Separate Phase 2 and Phase 3 trial results
- Mechanistic differences (triple vs dual agonist)
What we need: A direct head-to-head trial with both drugs studied in the same population using the same protocols.
Sources
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. Link
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. Link
- SUN-659 Comparative Efficacy and Safety of Tirzepatide vs Retatrutide in Weight Loss: A Network Meta-Analysis of Clinical Trials. J Endocr Soc. 2025;9(Supplement_1). Link
- Eli Lilly and Company. Lilly's phase 2 retatrutide results published in The New England Journal of Medicine. Press Release, June 24, 2023. Link
- Eli Lilly and Company. Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1. Press Release, April 28, 2022. Link
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. Link
- ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Participants With Obesity (TRIUMPH-1). NCT05508867. Link
- U.S. Food and Drug Administration. MOUNJARO (tirzepatide) injection Prescribing Information. May 2022. Link
- U.S. Food and Drug Administration. ZEPBOUND (tirzepatide) injection Prescribing Information. November 2023. Link
Last updated October 6, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.